Radioactive Preparation Carriers TRIZ Cases

Polyvalent acid trapping enables solid phase extraction purification, eliminating HPLC delays and preserving precursor structure.

Complexing agents bind toxic 212Pb daughter nuclides in 224Ra solutions, reducing off-target toxicity and extending shelf life.

An anti-uPA antibody binds active urokinase-type plasminogen activator to trigger receptor-mediated internalization.

Conjugates comprising immunoglobulin single variable domains labeled with zwitterionic fluorescent moieties exhibit exclusive renal clearance and low serum protein binding.

Fusing an albumin-binding domain with a HER2-targeting peptide prevents renal reabsorption, enhancing tumor delivery.

A multivalent glyco-complex links three glucose molecules to a central nitrogen atom via linkers and a chelating group.

Combining NTSR1-targeted radiopharmaceuticals with DNA damage response inhibitors reduces normal tissue toxicity while enhancing treatment efficacy.

A modified 18F-FACBC synthesis process replaces the alumina cartridge with a hydrophilic lipophilic balanced solid phase for purification.

Bifunctional molecules with tripodal hexadentate tris(hydroxypyridinone) chelators bind radionuclides at room temperature.

Radiolabeled antibodies enable precision dosing based on patient pharmacokinetics, addressing refractory non-Hodgkin lymphoma relapse.

Radiolabeled PSMA inhibitors bind to cancer cells for precise PET/CT signal identification, resolving late-stage anatomical detection limits.

A hydrophobic tag on the leaving group enables simple column chromatography purification of radioactive fluorine-labeled compounds.